Accenture's Petra Jantzer On Changing M&A Strategies
Executive Summary
In this episode of the In Vivo podcast, David Wild speaks with Petra Jantzer, senior managing director and global life sciences lead at Accenture, about the changing deals landscape. The discussion centers on the shifts in M&A strategies that Jantzer has been seeing among big pharmas and the need for other companies to adapt to a world in which technologies and processes become a key focus of growth.
As Accenture's Petra Jantzer tells In Vivo reporter David Wild, pharmas should consider shifting their M&A strategy if they want to achieve maximum growth. She reached that conclusion after observing that some of the biggest pharma companies are locking in more deals for technologies and platforms, not necessarily of the late-stage assets that have historically driven pipeline growth.
However, as Jantzer explains, following this type of pathway to growth requires more than simply redirecting the focus of investments; it calls for fundamental cultural and operational changes so that organizations can integrate and optimize the value of these new assets.
Time stamps:
0:30 Snapshot of Accenture M&A analysis
1:30 Four types of growth pathways and changing M&A trends
4:00 Acquisitions of new technologies, processes and platforms
5:27 Examples of success
7:19 Keys to successfully pursuing a new M&A strategy
11:17 Deals, the digital revolution and the metaverse
15:15 Key takeaways